CSF Biomarkers and Incipient Alzheimer Disease in Patients with Mild Cognitive Impairment
JAMA 302:385-393,436,452, Mattsson,N.,et al, 2009
Revised Criteria for Diagnosis and Staging of Alzheimers Disease: Alzheimers Association Workgroup
Alzheimers Dement 20:5143-5169, Jack,Jr.,C.R.,et al, 2024
Toward Gerineuropalliative Care for Patients with Dementia
NEJM 389:775-778, Harrison,K.L.,et al, 2023
Practice Guide Update Summary: Mild Cognitive Impairment
Neurol 90:126-135, Petersen, R.C.,et al, 2018
Advanced Dementia
NEJM 372:2533-2540, Mitchell, S.L., 2015
CSF biomarkers in posterior cortical atrophy
Neurol 76:1782-1788, Seguin, J.et al, 2011
The Older Adult Driver with Cognitive Impairment: "Its a Very Frustrating Life"
JAMA 303:1632-1641, 1642, 1660, Carr,D.B. &Ott,B.R., 2010
Practice Parameter Update: Evaluation and Management of Driving Risk in Dementia: Report of the Quality Standards Subcommittee of the American Academy of Neurology
Neurol 74:1316-1324, Iverson,D.J., et al, 2010
Serial MRI and CSF Biomarkers in Normal Aging, MCI, and AD
Neurol 75:143-151, Vemuri,P., et al, 2010
Genetic Aspects of Alzheimer Disease
The Neurologist 15:80-86, Williamson,J.,et al, 2009
The Clinical Course of Advanced Dementia
NEJM 361:1529-1538, 1595, Mitchell,S.,et al, 2009
A 60-Year-Old Woman with Mild Memory Impairment: Review of Mild Cognitive Impairment
JAMA 300:1566-1574,1598, Ellison,J.M., 2008
Driving and Dementia
BMJ 334:1365-1369, Breen,D.A.,et al, 2007
Pharmacological treatment of Neuropsychiatric Symptoms of Dementia
JAMA 293:596-608, Sink,K.M.,et al, 2005
End-of-Life Care and the Effects of Bereavement on Family Caregivers of Persons with Dementia
NEJM 349:1936-1942,1891, Schulz,R.,et al, 2003
Evaluation of CSf-tau and CSF-AB42 as Diagnostic Markers for Alzheimer Disease in Clinical Practice
Arch Neurol 58:373-379,349, Andreasen,N.,et al, 2001
Early Detection of Dementia: Mild Cognitive Impairment (an Evidence-based Review)
Neurol 56:1133-1142, 1131, Petersen,R.C.,et al, 2001
Positron Emission Tomography in Evaluation of Dementia
JAMA 286:2120-2127,2194, Silverman,D.H.S.,et al, 2001
Practice Parameter: Risk of Driving and Alzheimer's Disease (An Evidence-Based Review)
Neurol 54:2205-2211, Dubinsky,R.M.,et al, 2000
Utility of the Apolipoprotein E Genotype in the Diagnosis of Alzheimer's Disease
NEJM 338:506-511, Mayeux,R.,et al, 1998
Longitudinal Study of CSF Levels of Tau, A beta 1-40, and A beta 1-42 (43) in Alzheimer's Disease
Ann Neurol 44:17-26, 61998., Kanai,M.,et al, 1998
The Clinical Introduction of Genetic Testing for Alzheimer Disease, An Ethical Perspective
JAMA 277:832-836, Post,S.G.,et al, 1997
Assessment of CSF Levels of Tau Protein in Mildly Demented Patients with Alzheimer's Disese
Neurol 48:632-635, Galasko,D.,et al, 1997
Evaluation of Dementia:A Systematic Study of the Usefulness of the AAN Practice parameters
Neurol 49:925-935, Chui,H.&Zhang,Q., 1997
Apolipoprotein E Genotyping in Alzheimer's Disease
Lancet 347:1091-1095, Tanzi,R.,et al, 1996
Diagnosis and Evaluation of Dementia
Neurol 45:211-218, Corey-Bloom,J.,et al, 1995
Statement of Use of Apolipoprotein E Testing for Alzheimer Disease
JAMA 274:1627-1629, Farrer,L.A.,et al, 1995
Medical Aspects of the Persistent Vegetative State
NEJM 330:1499-1508, 1572-15791994., Annas,G.J.,et al, 1994
Anomalous Molecular Form of Acetylcholinesterase in CSF in Histologically Diagnosed Alzheimer's Disease
Lancet 337:447-450, Navaratnam,D.S.,et al, 1991
Neuropeptides in Neurological Disease
Ann Neurol 20:547-565, Beal,M.F.&Martin,J.B., 1986
Cerebrospinal Fluid Acetylcholinesterase Activity in Senile Dementia of the Alzheimer Type
Ann Neurol 17:46-48, Tune,L.,et al, 1985
Oligoclonal IgG Bands in Cerebrospinal Fluid in Various Neurological Diseases
Ann Neurol 13:434-439, Chu,A.B.,et al, 1983